All In Biotech

Drug Trial Radar · NCT00974155

The Early Medication Change (EMC) Trial

Randomised Clinical Trial Comparing Early Medication Change (EMC) Strategy With Treatment as Usual (TAU) in Patients With Major Depressive Disorder - the EMC Trial

Last checked: Nov 19, 2026Latest source record: Apr 1, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 889 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

889

Actual

Start

Sep 2009

Primary completion

May 2014

Study completion May 2014

Sponsor

Lead sponsor
K. LiebAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
German Federal Ministry of Education and Research
First posted
Sep 10, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The EMC trial investigates for the first time prospectively whether Major Depression Disorder patients with non-improvement after 14 days of antidepressive treatment with EMC are more likely to become remitters compared to patients treated according to current guidelines, i.e., with a medication change after 28 days of treatment in case of non-response.

Conditions

  • Depression

Interventions

  • Escitalopram, venlafaxine, lithiumDrug

    oral application, highest tolerable dose, once daily

  • Escitalopram, venlafaxineDrug

    oral application, highest tolerable dose, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Remission from MDD on day 56, defined as a HAMD17 sum score ≤ 7, in non-improvers on day 14 (n=192)Time frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Medical Center of the Johannes Gutenberg-University

    Mainz, Rhineland-Palatinate, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.